NTBL vs. SNOA, SXTP, CWBR, CNSP, SLRX, ATXI, CYTO, VRPX, DRMA, and ONCO
Should you be buying Notable Labs stock or one of its competitors? The main competitors of Notable Labs include Sonoma Pharmaceuticals (SNOA), 60 Degrees Pharmaceuticals (SXTP), CohBar (CWBR), CNS Pharmaceuticals (CNSP), Salarius Pharmaceuticals (SLRX), Avenue Therapeutics (ATXI), Altamira Therapeutics (CYTO), Virpax Pharmaceuticals (VRPX), Dermata Therapeutics (DRMA), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.
Sonoma Pharmaceuticals (NASDAQ:SNOA) and Notable Labs (NASDAQ:NTBL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
Sonoma Pharmaceuticals has higher revenue and earnings than Notable Labs. Notable Labs is trading at a lower price-to-earnings ratio than Sonoma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Sonoma Pharmaceuticals received 210 more outperform votes than Notable Labs when rated by MarketBeat users. However, 100.00% of users gave Notable Labs an outperform vote while only 67.50% of users gave Sonoma Pharmaceuticals an outperform vote.
In the previous week, Notable Labs had 6 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 8 mentions for Notable Labs and 2 mentions for Sonoma Pharmaceuticals. Notable Labs' average media sentiment score of 1.03 beat Sonoma Pharmaceuticals' score of 0.60 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media.
2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 70.5% of Notable Labs shares are held by institutional investors. 9.2% of Sonoma Pharmaceuticals shares are held by insiders. Comparatively, 1.2% of Notable Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Notable Labs has a net margin of 0.00% compared to Notable Labs' net margin of -41.24%. Notable Labs' return on equity of -58.93% beat Sonoma Pharmaceuticals' return on equity.
Sonoma Pharmaceuticals presently has a consensus price target of $3.25, suggesting a potential upside of 1,811.76%. Notable Labs has a consensus price target of $8.00, suggesting a potential upside of 661.90%. Given Notable Labs' higher possible upside, research analysts clearly believe Sonoma Pharmaceuticals is more favorable than Notable Labs.
Sonoma Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Notable Labs has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.
Summary
Sonoma Pharmaceuticals beats Notable Labs on 11 of the 17 factors compared between the two stocks.
Get Notable Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for NTBL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NTBL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Notable Labs Competitors List
Related Companies and Tools
